DLM: Fiber (2007)

Citation:
 
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:

The purpose of this study was to conduct a pooled analysis of dietary fiber and its sub-types and risk of coronary heart disease.

 

Inclusion Criteria:
  • Published prospective study
  • At least 150 incident coronary cases
  • Assessment of usual dietary intake and a validation study of diet assessment method or closely-related instrument.

 

 

Exclusion Criteria:
  • Absence of dietary fiber intake data
  • Investigators do not agree to include data.
Description of Study Protocol:
  • Studies were identified through literature searches and inquiring with experts in the field
  • Study quality was not assessed.

 

Data Collection Summary:
  • In all studies, diet was measured at baseline using a food frequency questionnaire (nine studies) or diet history instrument (one study)
  • Investigators examined:
    • Total dietary fiber
    • Fiber intake from three different food group sources (cereals, fruits and vegetables)
    • Insoluble fiber (hemicellulose, cellulose and lignins)
    • Soluble fiber (pecans, gums and mucilage)
  • *Fiber from cereals, fruits and vegetables was available for all studies with exceptions of two
  • *A wide variety of foods contributed to each fiber type with the relative contribution from certain foods varying among studies
  • *Starchy vegetables, such as corn and peas, contributed substantially to vegetable fiber in all studies
  • *Only six studies had estimates of insoluble and soluble fiber
  • Standardized criteria were used to ascertain cases of fatal and non-fatal acute myocardial infarction in all studies.  Because one study had only self-reported data on incidents of CHD, investigators only used fatal coronary cases from this study.
  • Three regression models were computed:
    • Model 1: Age (in years), energy intake (kcal per day), smoking status (never or current) and dose (1 to 4, 5 to 15, 15 to 24, and >25 per day), body mass index (<23, 23 to <25, 25 to <27.5, 27.5 to <30 or >30), physical activity (levels 1 to 5), education (less than high school, high school, more than high school), alcohol intake, multiple vitamin use (yes or no), hypercholesterolemia (yes or no) and hypertension (yes or no).
    • Model 2: Covariates in Model 1 and energy-adjusted quintiles of dietary saturated fat, polyunsaturated fat and cholesterol
    • Model 3: Covariates in Model 2 and also energy-adjusted quintiles of dietary and supplement sources of folic acid and vitamin E
  • Before performing the regression analysis, dietary fiber and all dietary covariates were adjusted within each study for energy intake
  • Investigators analyzed the energy-adjusted dietary fiber as a continuous variable (increment of 10g per day)

 

Description of Actual Data Sample:
  • 10 articles were included
  • 14 articles were identified
  • *3 investigators chose not to include data
  • *1 did not included data on dietary fiber
  • All studies were prospective cohorts:
    • 91,058 men
    • 245,186 women
    • 2,506,581 person-years of follow-up
  • Number of cardiovascular events:
    • 5,249 events
    • 2,011 fatal cases.
Summary of Results:
  • In analysis adjusted for all demographic and non-dietary lifestyle factors, for each 10g per day increment in dietary fiber, investigators observed pooled reductions in risk of 12% for all coronary events and 19% for coronary deaths. There was little attenuation of pooled estimates with adjustment for Model 2 and Model 3 (Table 1).
  • With adjustment for all demographic, lifestyle and dietary factors: Investigators observed pooled reductions in risk of all coronary events of 10% for each 10g per day increment of cereal and 16% per 10g per day increment of fruit fiber, although the finding for cereal fiber had a CI that included 1.00 (Table 2). 
  • Associations were stronger for coronary deaths than for all events, with reductions in risk of 25% for cereal fiber and 30% for fruit fiber for each 10g per day increment. 
  • Vegetable fiber was not associated with CHD incidence or mortality
  • To determine if the associations observed for cereal and fruit fiber were independent, investigators included these fiber types in the same regression model. The results were similar for:
    • All events:
      • Fruit fiber: RR 0.81; CI 0.69 to 0.95
      • Cereal fiber: RR 0.89; CI 0.76 to 1.05
    • Deaths:
      • Fruit fiber: RR 0.65; CI 0.49 to 0.86
      • Cereal fiber: RR 0.71; CI 0.59 to 0.87 
  • Associations were stronger for soluble fiber than insoluble fiber
    • Soluble: 
      • All events: RR per 10g per day increment, 0.72; CI, 0.55 to 0.93
      • Deaths: RR, 0.46; CI 0.28 to 0.74
    • Insoluble: 
      • All events: RR per 10g per day increment, 0.90; CI 0.83 to 0.97
      • Deaths RR, 0.80; CI 0.69 to 0.92 
  • The only observation of heterogeneity in RRs was for the analysis of cereal fiber and total coronary events, in which three cohorts of women had RRs greater than 1.00 (Table 2). 

Table 1 Study-Specific and Pooled Multivariate Relative Risks (95% Confidence Intervals) of Coronary Heart Disease per 10g per day increments of Total Dietary Fiber

Studies

All Events

Deaths

 

Model 1

Model 2

Model 3

Model 1

Model 2

Model 3

AHS

 

 

 

 

 

 

Men

0.84

0.89

1.04 (0.43-2.57)

0.56

0.22

0.32 (0.05-2.18)

Women

1.39

1.53

1.44 (0.46-4.36)

1.55

1.45

1.85 (0.28-12.1)

ARIC

 

 

 

 

 

 

Men

0.94

1.00

1.02 (0.74-1.40)

0.70

0.71

0.54 (0.19-1.57)

Women

0.66

0.67

0.73 (0.39-1.34)

0.70

---

---

ATBC (men only)

0.96

0.95

0.96 (0.85-1.09)

0.84

0.81

0.84 (0.69-1.03)

FMC

 

 

 

 

 

 

Men

0.89

0.89

0.97 (0.74-1.28)

0.83

0.73

0.74 (0.49-1.12)

Women

0.61

0.58

0.74 (0.42-1.31)

0.59

0.44

0.33 (0.09-1.22)

GPS

 

 

 

 

 

 

Men

0.87

0.83

0.93 (0.54-1.59)

1.00

1.53

1.66 (0.66-4.20)

Women

1.02

1.44

1.00 (0.34-2.98)

0.94

0.81

0.37 (0.04-3.91)

HPFS

0.85

0.84

0.87 (0.78-0.92)

0.77

0.82

0.84 (0.69-1.03)

IWHS

---

---

---

0.78

0.78

0.80 (0.61-1.04)

NHSa

0.95

0.94

0.96 (0.72-1.27)

1.05

1.14

0.96 (0.55-1.67)

NHSb

0.84

0.82

0.87 (0.72-1.05)

0.79

0.81

0.75 (053-1.02)

VIP

 

 

 

 

 

 

Men

0.95

0.82

0.91 (0.63-1.31)

0.69

0.55

0.53 (0.24-1.15)

Women

1.11

2.02

3.18 (0.98-10.37

0.65

---

---

WHS

0.75

0.74

0.77 (0.50-1.17)

1.46

4.70

1.77 (0.24-12.90)

 

 

 

 

 

 

 

Pooled

0.88 (0.84-0.93)

0.88 (0.83-0.94)

0.81

0.81 (0.74-0.88)

0.81(0.72-0.92)

0.81 (0.73-0.91)

P-value for relative risk

<0.001

<0.001

0.005

<0.001

0.001

<0.001

P-value for heterogeneity

0.42

0.39

0.82

0.85

0.29

0.73

After measurement error correction

 

 

0.85 (0.78-0.96)

 

 

0.73 (0.61-0.87)

P-value for relative risk†

 

 

0.005

 

 

<0.001

P-value for heterogeneity ‡

 

 

0.93

 

 

0.83

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Abbreviations: Adventists  Health Study (AHS), Atherosclerosis Risk in Communities Study (ARIC), Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC), Finnish Mobile Clinic Health Examination Survey (FMC), Glostrup Population Study (GPS), Health Professionals Follow-up Study (HPFS), Iowa Women’s Health Study (IWHS), Nurses Health Study 1980 to 1986 (NHSa), Nurses Health Study 1986 to 1996 (NHSb), Vasterbotten Intervention Program (VIP), Women’s Health Study (WHS).

*Model 1 includes age, energy intake, smoking status and dose, body mass index, physical activity, education, alcohol intake, multiple vitamin use, hypercholesterolemia and hypertension. Model 2: Covariates in Model 1 and energy-adjusted quintiles of dietary saturated fat, polyunsaturated fat and cholesterol. Model 3: Covariates in Model 2 and also energy-adjusted quintiles of dietary and supplement sources of folic acid and vitamin E.

  † P-value, test for no association

  ‡ P-value, test for between-studies heterogeneity. 

Table 2. Study-Specific and Pooled Multivariate Relative Risks (95% Confidence Intervals) of Coronary Heart Diease per 10g per day Increments of Cereal Fiber, Fruit Fiber and Vegetable Fiber

Studies

All Events

Deaths

 

Cereal

Fruit

Vegetable

Cereal

Fruit

Vegetables

ARIC

 

 

 

 

 

 

Men

0.68

0.90

1.17

0.90

0.20

1.79

Women

1.95

0.54

1.62

---

---

---

ATBC (men only)

1.02

0.72

0.64

0.94

0.41

0.57

FMC

 

 

 

 

 

 

Men

0.95

1.27

1.00

0.82

1.10

0.34

Women

0.75

1.49

0.47

0.44

0.25

1.97

HPFS

0.77

0.76

0.98

0.68

0.74

1.13

IWHS

----

---

---

0.49

0.70

0.98

NHSa

1.69

0.74

1.07

1.34

0.95

1.10

NHSb

0.66

1.02

1.16

0.61

0.92

0.98

VIP

 

 

 

 

 

 

Men

0.83

1.30

1.24

0.54

0.12

3.11

Women

3.52

8.23

0.09

---

---

---

WHS

0.93

0.45

0.90

0.03

3.93

0.44

 

 

 

 

 

 

 

Pooled

0.90 (0.77-1.07)

0.84 (0.74-0.88)

1.00 (0.88-1.13)

0.75 (0.63-0.89)

0.70 (0.55-0.89)

1.00 (0.82-1.23)

P-value for relative risk†

0.23

0.04

0.97

0.003

0.004

0.97

P-value for heterogeneity‡

0.02

0.24

0.46

0.30

0.39

0.46

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Abbreviations: Atherosclerosis Risk in Communities Study (ARIC), Alpha-Tocopherol Beta-Carotene Cancer Prevention Study (ATBC), Finnish Mobile Clinic Health Examination Survey (FMC), Health Professionals Follow-up Study (HPFS), Iowa Women’s Health Study (IWHS), Nurses Health Study 1980 to1986 (NHSa), Nurses Health Study 1986 to 1996 (NHSb), Vasterbotten Intervention Program (VIP), Women Health Study  (WHS). 

*Model 1 includes age, energy intake, smoking status and dose, BMI, physical activity, education, alcohol intake, multiple vitamin use, hypercholesterolemia and HTN. Model 2: Covariates in Model 1 and energy-adjusted quintiles of dietary saturated fat, polyunsaturated fat and cholesterol. Model 3: Covariates in Model 2 and also energy-adjusted quintiles of dietary and supplement sources of folic acid and vitamin E.

     † P-value, test for no association

     ‡ P-value, test for between-studies heterogeneity.

Author Conclusion:
  • Dietary fiber intake during adulthood is inversely associated with CHD risk. Coronary risk was 10% to 30% lower for each 10g per day increment of total, cereal or fruit fiber. 
  • Cereal and fruit fiber had strong inverse associations with CHD risk
  • No such associations were observed for vegetable fiber
  • These associations seemed to be independent of other dietary factors, sex, age, baseline body mass index, smoking, history of hypertension, diabetes and hypercholesterolemia 
  • The only observation of heterogeneity in RRs was for the analysis of cereal fiber and total coronary events, in which three cohorts of women had RRs greater than 1.00.

 

Funding Source:
Government: NIDDK, NIH
Industry:
General Mills
Food Company:
Not-for-profit
0
Foundation associated with industry:
Reviewer Comments:
  • Inverse associations for both types of fiber are presented in the analysis, but only six studies estimated insoluble and soluble fiber, and there is no standard method used to derive these estimates 
  • The information from this study is generalizable to the adult population.
Quality Criteria Checklist: Primary Research
Relevance Questions
  1. Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) Yes
  2. Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? Yes
  3. Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? ???
  4. Is the intervention or procedure feasible? (NA for some epidemiological studies) ???
 
Validity Questions
1. Was the research question clearly stated? Yes
  1.1. Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? Yes
  1.2. Was (were) the outcome(s) [dependent variable(s)] clearly indicated? Yes
  1.3. Were the target population and setting specified? Yes
2. Was the selection of study subjects/patients free from bias? Yes
  2.1. Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? Yes
  2.2. Were criteria applied equally to all study groups? ???
  2.3. Were health, demographics, and other characteristics of subjects described? Yes
  2.4. Were the subjects/patients a representative sample of the relevant population? Yes
3. Were study groups comparable? Yes
  3.1. Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) ???
  3.2. Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? Yes
  3.3. Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) ???
  3.4. If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? ???
  3.5. If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) ???
  3.6. If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? ???
4. Was method of handling withdrawals described? Yes
  4.1. Were follow-up methods described and the same for all groups? Yes
  4.2. Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) ???
  4.3. Were all enrolled subjects/patients (in the original sample) accounted for? ???
  4.4. Were reasons for withdrawals similar across groups? ???
  4.5. If diagnostic test, was decision to perform reference test not dependent on results of test under study? ???
5. Was blinding used to prevent introduction of bias? ???
  5.1. In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? ???
  5.2. Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) ???
  5.3. In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? ???
  5.4. In case control study, was case definition explicit and case ascertainment not influenced by exposure status? ???
  5.5. In diagnostic study, were test results blinded to patient history and other test results? ???
6. Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? ???
  6.1. In RCT or other intervention trial, were protocols described for all regimens studied? ???
  6.2. In observational study, were interventions, study settings, and clinicians/provider described? ???
  6.3. Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? ???
  6.4. Was the amount of exposure and, if relevant, subject/patient compliance measured? ???
  6.5. Were co-interventions (e.g., ancillary treatments, other therapies) described? ???
  6.6. Were extra or unplanned treatments described? ???
  6.7. Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? ???
  6.8. In diagnostic study, were details of test administration and replication sufficient? ???
7. Were outcomes clearly defined and the measurements valid and reliable? ???
  7.1. Were primary and secondary endpoints described and relevant to the question? Yes
  7.2. Were nutrition measures appropriate to question and outcomes of concern? ???
  7.3. Was the period of follow-up long enough for important outcome(s) to occur? ???
  7.4. Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? ???
  7.5. Was the measurement of effect at an appropriate level of precision? ???
  7.6. Were other factors accounted for (measured) that could affect outcomes? ???
  7.7. Were the measurements conducted consistently across groups? N/A
8. Was the statistical analysis appropriate for the study design and type of outcome indicators? Yes
  8.1. Were statistical analyses adequately described and the results reported appropriately? Yes
  8.2. Were correct statistical tests used and assumptions of test not violated? Yes
  8.3. Were statistics reported with levels of significance and/or confidence intervals? Yes
  8.4. Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? Yes
  8.5. Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? Yes
  8.6. Was clinical significance as well as statistical significance reported? Yes
  8.7. If negative findings, was a power calculation reported to address type 2 error? Yes
9. Are conclusions supported by results with biases and limitations taken into consideration? Yes
  9.1. Is there a discussion of findings? Yes
  9.2. Are biases and study limitations identified and discussed? Yes
10. Is bias due to study's funding or sponsorship unlikely? Yes
  10.1. Were sources of funding and investigators' affiliations described? Yes
  10.2. Was the study free from apparent conflict of interest? Yes